Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Size to Grow by USD 1.79 billion, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio |
| July 25, 2022 | July 2022 Bond Updates |
|
NEW YORK, July 25, 2022 /PRNewswire/ -- DLBCL is a cancer of B-lymphocytes and is the most common type of Non-Hodgkins Lymphoma (NHL) among adults. It is a fast-growing and complex form of NHL and is difficult to treat. NHL refers to a group of cancers of the lymphatic system that... |
| View more at: https://www.prnewswire.com:443/news-releases/diffuse-large-b-cell-lymphoma-dlbcl-therapeutics-market-size-to-grow-by-usd-1-79-billion-abbvie-inc-and-bayer-ag-among-key-vendors---technavio-301591925.html |
| Related News |
|